Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

Malaria parasites undergo an extensive metamorphosis after invasion of erythrocytes. This induces an increase in the surface ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II ...

Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime ...

Iovance stock drops 90% despite historic approval for Amtagvi. Click here for a full investment analysis of IOVA stock.

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in Parkinson's patients dosed with ...

Cerevance's solengepras failed to meet its primary endpoint in the ASCEND trial, which sought to evaluate it as a monotherapy ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Roche outlined the effectiveness of ...

The following is a summary of “YouTube as a source of information for stroke rehabilitation: a cross-sectional analysis of ...